keyword
MENU ▼
Read by QxMD icon Read
search

Omalizumab

keyword
https://www.readbyqxmd.com/read/28734860/the-expanding-field-of-biologics-in-the-management-of-chronic-urticaria
#1
Shyam Joshi, David A Khan
Chronic urticaria (CU) is the occurrence of urticaria with or without angioedema for at least 6 weeks. Management has traditionally involved antihistamines as first-line therapy with various alternative therapies for refractory cases. Largely based on the success of biologics for various diseases, this class of drugs has come to the forefront of medical research. The first and only Food and Drug Administration-approved biologic for the management of CU is omalizumab (humanized anti-IgE mAb). In the past decade, a substantial amount of research has been centered on the mechanism of action, efficacy, dosing, and safety of omalizumab...
July 19, 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28725641/mechanisms-mediating-pediatric-severe-asthma-and-potential-novel-therapies
#2
REVIEW
Aldara Martin Alonso, Sejal Saglani
Although a rare disease, severe therapy-resistant asthma in children is a cause of significant morbidity and results in utilization of approximately 50% of health-care resources for asthma. Improving control for children with severe asthma is, therefore, an urgent unmet clinical need. As a group, children with severe asthma have severe and multiple allergies, steroid resistant airway eosinophilia, and significant structural changes of the airway wall (airway remodeling). Omalizumab is currently the only add-on therapy that is licensed for use in children with severe asthma...
2017: Frontiers in Pediatrics
https://www.readbyqxmd.com/read/28722454/-chronic-urticaria-new-views-on-diagnosis-and-treatment-of-disease
#3
Dana Prusíková
Interest in chronic urticaria has grown in recent years, largely owing to the advent of new modes treatment especially in the form of the biologic preparation omalizumab. New scientific and clinical findings have not only facilitated a more comprehensive view of the disease but have streamlined the classification and diagnostic approach as well. Diagnostics are no longer burdened by cumbersome and lengthy investigative procedures into the etiology of urticaria, but are much more rapid and targeted bringing about more timely relief of the patient's symptoms...
2017: Casopís Lékar̆ů C̆eských
https://www.readbyqxmd.com/read/28721017/targeted-therapy-in-severe-asthma-today-focus-on-immunoglobulin-e
#4
REVIEW
Girolamo Pelaia, Giorgio Walter Canonica, Andrea Matucci, Rossella Paolini, Massimo Triggiani, Pierluigi Paggiaro
Asthma is a complex chronic inflammatory disease of multifactorial etiology. International guidelines increasingly recognize that a standard "one size fits all" approach is no longer an effective approach to achieve optimal treatment outcomes, and a number of disease phenotypes have been proposed for asthma, which has the potential to guide treatment decisions. Among the many asthma phenotypes, allergic asthma represents the widest and most easily recognized asthma phenotype, present in up to two-thirds of adults with asthma...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28720253/pulmonary-actinomycosis-in-a-patient-with-chronic-eosinophilic-pneumonia-treated-with-omalizumab
#5
Marta Erro Iribarren, Carolina Cisneros Serrano, Olga Rajas Naranjo, Elena García Castillo
No abstract text is available yet for this article.
July 15, 2017: Archivos de Bronconeumología
https://www.readbyqxmd.com/read/28719697/diagnosis-and-management-of-asthma-in-adults-a-review
#6
Jennifer L McCracken, Sreenivas P Veeranki, Bill T Ameredes, William J Calhoun
Importance: Asthma affects about 7.5% of the adult population. Evidence-based diagnosis, monitoring, and treatment can improve functioning and quality of life in adult patients with asthma. Observations: Asthma is a heterogeneous clinical syndrome primarily affecting the lower respiratory tract, characterized by episodic or persistent symptoms of wheezing, dyspnea, and cough. The diagnosis of asthma requires these symptoms and demonstration of reversible airway obstruction using spirometry...
July 18, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28709817/evaluation-of-a-guidelines-based-approach-to-the-treatment-of-chronic-spontaneous-urticaria
#7
Jorge Sánchez, Josefina Zakzuk, Ricardo Cardona
BACKGROUND: International scientific associations have made recommendations for the management of chronic spontaneous urticaria (CSU) that have been summarized in clinical guidelines. OBJECTIVE: To evaluate the clinical impact of guideline recommendations for CSU management. METHODS: A multicenter, triple-blinded, prospective, randomized study (the Urticaria Research of Tropical Impact and Control Assessment project; ClinicalTrials.gov identifier: NCT01940393) was performed...
July 11, 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28708944/indirect-comparison-of-bronchial-thermoplasty-versus-omalizumab-for-uncontrolled-severe-asthma
#8
Robert M Niven, Michael R Simmonds, Michael J Cangelosi, Dominic P Tilden, Suzanne Cottrell, Narinder S Shargill
OBJECTIVE: Bronchial thermoplasty (BT) as an add-on therapy for uncontrolled severe asthma is an alternative to biologic therapies like omalizumab (OM). We conducted an indirect treatment comparison (ITC) to appraise comparative effectiveness of BT and OM. METHODS: A systematic literature review identified relevant randomized controlled trials. The ITC followed accepted methodology. RESULTS: The ITC comprised a sham-controlled trial of BT (AIR2) and two placebo-controlled trials of OM (INNOVATE; EXTRA)...
July 14, 2017: Journal of Asthma: Official Journal of the Association for the Care of Asthma
https://www.readbyqxmd.com/read/28707471/one-step-identification-of-antibody-degradation-pathways-using-fluorescence-signatures-generated-by-cross-reactive-dna-based-arrays
#9
Shunsuke Tomita, Ayumi Matsuda, Suguru Nishinami, Ryoji Kurita, Kentaro Shiraki
Therapeutic antibodies are prone to degradation via a variety of pathways during each stage of the manufacturing process. Hence, a low-cost, rapid, and broadly applicable tool that is able to identify when and how antibodies degrade would be highly desirable to control the quality of therapeutic antibody products. With this goal in mind, we have developed signature-based sensing system to discriminate differently degraded therapeutic antibodies. The use of arrays consisting of conjugates between nanographene oxide and fluorophore-modified single-stranded DNAs under acidic pH conditions generated unique fluorescence signatures for each state of the antibodies...
July 18, 2017: Analytical Chemistry
https://www.readbyqxmd.com/read/28691309/serial-d-dimer-plasma-levels-in-a-patient-with-chronic-spontaneous-urticaria-developing-resistance-to-omalizumab
#10
R Asero
Chronic spontaneous urticaria (CSU) is a condition presenting as the spontaneous occurrence of itchy weals with or without angio-oedema for > 6 weeks. A patient with severe chronic spontaneous urticaria who developed resistance to omalizumab is described. The patient's D-dimer plasma levels strictly paralleled the disease activity despite the administration of anti-IgE therapy.
July 10, 2017: Clinical and Experimental Dermatology
https://www.readbyqxmd.com/read/28671445/acute-and-chronic-urticaria-evaluation-and-treatment
#11
Paul Schaefer
Urticaria commonly presents with intensely pruritic wheals, sometimes with edema of the subcutaneous or interstitial tissue. It has a lifetime prevalence of about 20%. Although often self-limited and benign, it can cause significant discomfort, continue for months to years, and uncommonly represent a serious systemic disease or life-threatening allergic reaction. Urticaria is caused by immunoglobulin E- and non-immunoglobulin E-mediated release of histamine and other inflammatory mediators from mast cells and basophils...
June 1, 2017: American Family Physician
https://www.readbyqxmd.com/read/28662309/omalizumab-prevents-anaphylaxis-and-improves-symptoms-in-systemic-mastocytosis-efficacy-and-safety-observations
#12
Sigurd Broesby-Olsen, Hanne Vestergaard, Charlotte Gotthard Mortz, Britt Jensen, Troels Havelund, Anne Pernille Hermann, Frank Siebenhaar, Michael Boe Møller, Thomas Kielsgaard Kristensen, Carsten Bindslev-Jensen
BACKGROUND: Patients with systemic mastocytosis (SM) may suffer from mast cell (MC) mediator-related symptoms insufficiently controlled by conventional therapy. Omalizumab is an established treatment in other MC-driven diseases, but experiences in SM are limited. OBJECTIVE: To assess the efficacy and safety of omalizumab in SM. METHODS: In our patient cohort we evaluated all SM patients treated with omalizumab. A physician global assessment of type and severity of symptoms was performed at baseline, at 3 and 6 months and at latest follow-up...
June 29, 2017: Allergy
https://www.readbyqxmd.com/read/28652400/activation-of-human-basophils-by-a549-lung-epithelial-cells-reveals-a-novel-ige-dependent-response-independent-of-allergen
#13
John T Schroeder, Anja P Bieneman
Evidence for epithelial cell (EC)-derived cytokines (e.g., thymic stromal lymphopoietin [TSLP]) activating human basophils remains controversial. We therefore hypothesize that ECs can directly activate basophils via cell-to-cell interaction. Basophils in medium alone or with IL-3 ± anti-IgE were coincubated with TSLP, IL-33, or IL-25. Analogous experiments cocultured basophils (1-72 h) directly with EC lines. Supernatants were tested for mediators and cytokines. Abs targeting receptors were tested for neutralizing effects...
June 26, 2017: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/28651294/-ige-and-anti-ige-in-asthma-a-chequered-history
#14
M Lommatzsch, K Geißler, K-C Bergmann, J Christian Virchow
A long and winding road led to the discovery of immunoglobulin E (IgE) in 1966 and 1967. We are currently on a long and winding road to understand the immunologic basis of the clinical effects of the anti-IgE antibody omalizumab in asthma. It is possible that patients with asthma (as patients with chronic spontaneous urticaria) benefit in different immunologic ways from omalizumab treatment. This article reviews the history of IgE discovery and current concepts of anti-IgE therapy in asthma.
June 2017: Pneumologie
https://www.readbyqxmd.com/read/28649751/long-term-management-of-chronic-spontaneous-urticaria-with-omalizumab
#15
M Pinto Gouveia, A Gameiro, A Pinho, M Gonçalo
BACKGROUND: Clinical trials have shown the efficacy of omalizumabs efficacy in refractory chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), but real-life management strategies are lacking. AIM: To assess the long-term efficacy and safety of omalizumab, and to identify predictive factors and optimum dosage regimens. METHODS: This was a prospective study of 13 patients (11 women, 2 men) with severe CSU [weekly urticaria activity score (UAS7) > 28] resistant to anti-H1 antihistamines...
June 25, 2017: Clinical and Experimental Dermatology
https://www.readbyqxmd.com/read/28647457/quantitative-in-vitro-and-in-vivo-models-to-assess-human-ige-b-cell-receptor-crosslinking-by-ige-and-empd-ige-targeting-antibodies
#16
Benjamin Vigl, Nina Salhat, Michela Parth, Halyna Pankevych, Andreas Mairhofer, Stefan Bartl, Oskar W Smrzka
Targeting plasma IgE by therapeutic mABs like Omalizumab (Xolair®) is current clinical practice for severe allergic conditions or other IgE related diseases like chronic urticaria. As an alternative to soluble IgE targeting, IgE supply can be lowered by targeting the Extracellular Membrane Proximal Domain (EMPD) of the IgE B cell receptor (BCR) present on IgE switched B cells. This ultimately leads to apoptosis of these cells upon IgE BCR crosslinking. Since tools to selectively assess the efficacy of IgE BCR crosslinking by IgE targeting antibodies are limited, a readily quantifiable cell model was developed that allows to specifically address IgE BCR crosslinking activity in vitro...
June 21, 2017: Journal of Immunological Methods
https://www.readbyqxmd.com/read/28635659/divergent-how-ige-axis-contributes-to-the-continuum-of-allergic-asthma-and-anti-ige-therapies
#17
REVIEW
Óscar Palomares, Silvia Sánchez-Ramón, Ignacio Dávila, Luis Prieto, Luis Pérez de Llano, Marta Lleonart, Christian Domingo, Antonio Nieto
Asthma is an airway disease characterised by chronic inflammation with intermittent or permanent symptoms including wheezing, shortness of breath, chest tightness, and cough, which vary in terms of their occurrence, frequency, and intensity. The most common associated feature in the airways of patients with asthma is airway inflammation. In recent decades, efforts have been made to characterise the heterogeneous clinical nature of asthma. The interest in improving the definitions of asthma phenotypes and endotypes is growing, although these classifications do not always correlate with prognosis nor are always appropriate therapeutic approaches...
June 21, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28631599/efficacy-and-safety-of-omalizumab-in-children-and-adolescents-with-moderate-to-severe-asthma-a-systematic-literature-review
#18
Jonathan Corren, Abhishek Kavati, Benjamin Ortiz, Jennifer A Colby, Kimberly Ruiz, Brett A Maiese, Sarah M Cadarette, Reynold A Panettieri
BACKGROUND: There are limited pediatric data about the use of omalizumab, especially the effectiveness and safety of omalizumab in the real-world management of allergic asthma. OBJECTIVE: The objective of this study was to summarize the safety and efficacy of omalizumab in both randomized clinical trials (RCT) used for U.S. Food and Drug Administration registration and real-world studies (RWS) based on clinical care of children with moderate-to-severe asthma. METHODS: Studies that evaluated omalizumab use in patients <18 years old and with asthma, published between January 2003 and October 2016, were retrieved from medical literature data bases...
July 1, 2017: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/28622052/biologic-treatment-eligibility-for-real-world-patients-with-severe-asthma-the-ideal-study
#19
Frank C Albers, Hana Müllerová, Necdet B Gunsoy, Ji-Yeon Shin, Linda M Nelsen, Eric S Bradford, Sarah M Cockle, Robert Y Suruki
OBJECTIVES: Severe asthma comprises several distinct phenotypes. Consequently, patients with severe asthma can be eligible for more than one biologic treatment targeting Th2 inflammation, such as anti-interleukin (IL)-5 and anti-immunoglobulin (Ig) E. The objective of this study was to describe treatment eligibility and overlap in treatment eligibility for mepolizumab (anti-IL-5), omalizumab (anti-IgE) and reslizumab (anti-IL-5) in patients with severe asthma, who were recruited from clinical practice...
June 16, 2017: Journal of Asthma: Official Journal of the Association for the Care of Asthma
https://www.readbyqxmd.com/read/28608756/effects-of-omalizumab-on-rhinovirus-infections-illnesses-and-exacerbations-of-asthma
#20
Ann Esquivel, William W Busse, Agustin Calatroni, Alkis G Togias, Kristine G Grindle, Yury A Bochkov, Rebecca S Gruchalla, Meyer Kattan, Carolyn M Kercsmar, G Khurana Hershey, Haejin Kim, Petra Lebeau, Andrew H Liu, Stanley J Szefler, Stephen J Teach, Joseph B West, Jeremy Wildfire, Jacqueline A Pongracic, James E Gern
RATIONALE: Allergic inflammation has been linked to increased susceptibility to viral illnesses, but it is unclear whether this association is causal. OBJECTIVE: To test whether omalizumab treatment to reduce IgE would shorten the frequency and duration of rhinovirus illnesses in children with allergic asthma. METHODS: The Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations (PROSE) was a study of children with allergic asthma (6-17 years, n=478) from low-income census tracts in 8 U...
June 13, 2017: American Journal of Respiratory and Critical Care Medicine
keyword
keyword
7812
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"